Loading page…
Loading page…
News stories updated
Two U.S. House committees are urging the federal government to restrict Chinese-developed open-weight AI models from federal systems, federal contract work and high-risk critical infrastructure. The recommendations follow a seven-month investigation into model provenance, cybersecurity, unauthorized distillation and the growing use of Chinese models by American companies including Airbnb, Anysphere and DoorDash. The report proposes 12 policy actions, including an American open-weight AI initiative, an AI bill of materials, new provenance standards, stronger threat sharing and tighter federal controls. The proposals are not enacted law, but they signal a widening U.S.–China technology contest in which AI model supply chains are beginning to receive scrutiny once reserved for semiconductors, telecommunications equipment and critical software. Read More...
NVIDIA has stopped shipping U.S.-licensed Hopper-generation data-center processors to China despite having regulatory permission to sell H200-class chips to approved Chinese customers. The company disclosed that it generated $2.4 billion from licensed Hopper sales to China during its fiscal third quarter, yet its current $130 billion fourth-quarter revenue outlook assumes no China data-center compute revenue. NVIDIA has not explained whether the halt is temporary or permanent. The decision comes as Washington tightens controls on advanced computing, Beijing restricts some imports while promoting domestic alternatives, and Chinese technology companies accelerate efforts to secure local AI infrastructure. The development could become an important turning point in the separation of American and Chinese AI-compute ecosystems. Read More...
Harbour BioMed says China’s National Medical Products Administration has accepted the Investigational New Drug application for LET003, its first AI-enabled obesity candidate developed using the company’s Hu-mAtrIx platform. LET003 targets activin receptors ACVR2A and ACVR2B and is designed to reduce fat while preserving or increasing lean mass, including in combination with GLP-1 therapies such as semaglutide. Harbour BioMed has reported encouraging animal data, but no human efficacy or safety results are available. The regulatory milestone is important because it moves an AI-assisted drug candidate further into formal development, while also highlighting a growing pharmaceutical race to improve the quality of weight loss rather than focusing only on the number of kilograms lost. Read More...